Atopic Dermatitis Drug Pipeline — PatSnap Eureka
Atopic Dermatitis Drug Pipeline: JAK Inhibitors, IL-4Rα & IL-31 Targeting
The AD pipeline is rapidly expanding across cytokine axis targeting — IL-4R, IL-13, IL-31RA — alongside JAK inhibitors and novel biologic approaches. Patent intelligence from PatSnap Eureka reveals who is filing, where, and what comes next.
Th2 Immune Dysregulation Drives the AD Pathogenic Axis
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease characterized by intense pruritus, eczematous lesions, and an underlying Th2-polarized immune response. The central pathogenic axis, evidenced across the majority of retrieved patents, involves dysregulated IL-4 and IL-13 signaling: both cytokines drive IgE sensitization, epidermal barrier disruption (including filaggrin deficiency), and maintenance of the inflammatory milieu. IL-4 and IL-13 share the IL-4Rα chain in their receptor complexes, making this subunit a high-priority pharmacological node. For broader context on dermatology and immunology research, NIH and the WHO provide foundational epidemiological data on AD global burden.
IL-31, signaling through IL-31RA, is highlighted in multiple retrieved filings as a primary pruritogen directly activating itch-sensory neurons, with the DOCK8/MST1/EPAS1/SP1 transcriptional axis identified as a regulator of IL-31 expression in CD4+ T cells. Retrieved literature further notes that IL-4 promotes neural hypersensitivity to IL-31 and other pruritogens such as thymic stromal lymphopoietin (TSLP) and histamine. Emerging targets in this dataset include IL-22R, OX40L, and IL-13Rα1. The PatSnap Life Sciences platform provides structured access to this growing patent landscape.
Biomarkers identified in retrieved results for AD include CCL20, CCL22, CCL27, VEGF, IL1RA, and CCL18 — upregulated in lesional skin and modulated by anti-IL-31RA therapy (nemolizumab). Patent and literature analysis via PatSnap Eureka surfaces these mechanistic signals across a rapidly expanding biologic pipeline.
Five Distinct Mechanistic Approaches in the AD Pipeline
Patent evidence from 2014 to 2026 reveals a pipeline stratified by target maturity — from commercially established IL-4Rα blockade to early-stage multispecific antibodies and microbiome-based approaches.
Anti-IL-4Rα Monoclonal Antibodies
The largest cluster of retrieved results — patents spanning 2014 through 2026 — covers anti-IL-4R antibodies for moderate-to-severe and severe AD. These agents block the IL-4Rα subunit shared by both type I and type II receptor complexes, simultaneously antagonizing IL-4 and IL-13 signaling. Regeneron Pharmaceuticals, Inc. holds more than 20 retrieved patents across at least 12 jurisdictions. Target populations include those with inadequate response to TCS, calcineurin inhibitors, or cyclosporine A, with pediatric extensions (ages 6 to <12) and atopic march prevention claims.
IGA · EASI · SCORAD · Pruritus NRS · BSAAnti-IL-31RA Monoclonal Antibodies (Nemolizumab)
Retrieved results from Chugai Seiyaku Kabushiki Kaisha and Galderma Holding SA describe anti-IL-31RA antibodies — specifically nemolizumab — for AD and prurigo nodularis. IL-31 drives pruritus by direct activation of itch-sensory neurons. The DOCK8/MST1/EPAS1 complex disruption in CD4+ T cells allows EPAS1 nuclear translocation and SP1-mediated IL-31 transcription. An AU filing references EASI-75 responder data (p=0.0041), indicating clinical trial evidence underlies the filing. Biomarkers CCL20, CCL22, CCL27, VEGF, IL1RA, and CCL18 are described as response predictors.
EASI-75 · p=0.0041 · Prurigo Nodularis ExtensionAnti-IL-13 Monoclonal Antibodies
A substantial cluster covers IL-13 antagonists including lebrikizumab (Genentech/Receptos), tralokinumab (MedImmune/AstraZeneca), and cendakimab (Receptos). These agents selectively block IL-13 without directly antagonizing IL-4. MedImmune filings address patients inadequately controlled by agents targeting both IL-13 and IL-4 signaling (e.g., dupilumab), positioning selective IL-13 targeting as a second-line biologic option. Dermira, Inc. patents address dosing regimens in dupilumab-experienced patients, signaling competitive differentiation through sequential positioning.
Dupilumab-Experienced Patients · Second-Line StrategyJAK Inhibitors
Two retrieved patents address JAK inhibitor approaches. Pfizer Inc. discloses pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamide scaffolds as JAK inhibitors with stated utility for JAK-mediated conditions including AD. Shenzhen Chipscreen Biosciences discloses a selective JAK3/JAK1/TBK1 inhibitor demonstrating efficacy in preclinical animal models. JAK inhibition suppresses Th2 cytokine signaling downstream of IL-4Rα (JAK1/JAK3-STAT6 pathway) and JAK1/TYK2-driven itch signaling via the IL-31 axis. The Chipscreen filing cites animal experiment data — no clinical signal retrieved in this dataset.
JAK3/JAK1/TBK1 · Preclinical Stage · Oral Route PotentialPatent Evidence Signals Across the AD Therapeutic Landscape
Data derived from patent and literature analysis via PatSnap Eureka. Represents a snapshot of innovation signals within this dataset only.
Regeneron IL-4Rα Patent Jurisdiction Coverage
Regeneron's anti-IL-4Rα (dupilumab) patent estate spans at least 12 jurisdictions, reflecting a globally distributed IP strategy from 2014 to 2026.
AD Pipeline: Development Stage Distribution
Patent evidence signals stratify the AD pipeline into four development stages — from commercial to early/IND-enabling — based on clinical data references and jurisdiction breadth.
Key Patent Holders in the Atopic Dermatitis Pipeline
Activity in this dataset is overwhelmingly patent-driven. The commercial IP landscape is highly concentrated among a small number of major players, with Regeneron/Sanofi dominating IL-4Rα and emerging challengers staking claims in dupilumab-experienced populations.
| Assignee | Target / Drug | Jurisdictions | Filing Range | Stage Signal |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | Anti-IL-4Rα (dupilumab) | US, EP, AU, JP, CA, IL, NZ, SG, MX, BR, PT, HK (12+) | 2014–2026 | Commercial |
| Sanofi Biotechnology | Anti-IL-4Rα (dupilumab, co-development) | RU, IN, KR, US/WO | 2018–2021 | Commercial |
| Chugai Seiyaku Kabushiki Kaisha | Anti-IL-31RA (nemolizumab) | WO, US, CA, AU | 2021–2024 | Late Clinical |
| Galderma Holding SA | Anti-IL-31RA (nemolizumab, co-development) | JP, KR, CN, BR | 2022–2024 | Late Clinical |
Track Competitor Patent Filings in Real Time
PatSnap Eureka monitors new AD filings across all assignees and jurisdictions — updated continuously.
Next-Generation Strategies Beyond the IL-4Rα Axis
Retrieved results signal several differentiated biologic and combination approaches representing the most nascent but strategically significant directions in the AD pipeline — areas with limited IP saturation and higher white-space opportunity.
Anti-IL-13Rα1 / Eblasakimab (ASLAN Pharmaceuticals)
Targeting the IL-13Rα1 receptor subunit rather than the ligand, with explicit focus on dupilumab-experienced patients (WO, 2023). This approach potentially exploits mechanistic differentiation at the receptor subunit level, offering a distinct patient response profile compared to IL-4Rα blockade.
Bispecific Anti-IL-13/IL-18 (Novartis AG, 2025)
A multispecific antibody simultaneously targeting IL-13 and IL-18, recognizing that IL-18 may contribute to Th1/Th17 dysregulation in AD subpopulations incompletely controlled by pure Th2 blockade. Filed in Indonesia (ID) in 2025, representing an area with limited IP saturation in this dataset.
Anti-IL-22R (Leo Pharma A/S, 2024)
IL-22R is selectively expressed on skin and epithelial cells, mediating signaling by IL-22, IL-20, and IL-24. An anti-IL-22R antibody for AD is filed as a WO application (2024), representing early-stage exploration of an additional inflammatory node in AD pathobiology beyond the dominant Th2 axis.
Microbiome-Based: Akkermansia muciniphila (Enterobiome Inc.)
An Enterobiome Inc. JP patent (2022) reports that Akkermansia muciniphila strain EB-AMDK19 demonstrates anti-atopic efficacy comparable to steroids in preclinical models, suggesting pharmabiotics as an emerging non-cytokine modality — a mechanistically distinct approach from all biologic and small-molecule strategies in this dataset.
What the Patent Evidence Signals for R&D and IP Strategy
IL-4Rα remains the dominant IP cluster in this dataset, with Regeneron/Sanofi holding a mature, globally distributed patent estate. New entrants should anticipate dense freedom-to-operate challenges in this space and will need to differentiate on patient subpopulation, dosing regimen, or combination claims. The PatSnap Analytics platform enables rapid freedom-to-operate assessment across these dense IP clusters.
The dupilumab-experienced patient population has emerged as a distinct IP and commercial opportunity, with MedImmune (tralokinumab), Dermira (lebrikizumab), ASLAN (eblasakimab), and Receptos (anti-IL-13) all filing claims specifically in this subgroup — signaling that competitive differentiation is increasingly driven by sequential or second-line positioning rather than head-to-head comparison. The European Bioinformatics Institute and FDA provide regulatory context for these emerging indications.
IL-31RA (nemolizumab) has established a distinct mechanistic niche centered on pruritus rather than inflammation per se, with biomarker-guided patient selection (CCL20, CCL22, CCL27, VEGF, IL1RA, CCL18) and extension to prurigo nodularis representing IP and clinical breadth strategies. JAK inhibitors in this dataset appear at an earlier patent maturity stage relative to biologics, with small-molecule selectivity profiles (JAK3/JAK1/TBK1) warranting monitoring for preclinical-to-IND progression, particularly given their oral route potential. PatSnap customers in pharma use these signals to prioritize R&D investment decisions.
Multispecific and bispecific antibody strategies (IL-13/IL-18; IL-4/IL-13 + plasma cell ablation) represent the most nascent but strategically significant emerging direction, as they may address heterogeneous AD endotypes not fully captured by single cytokine blockade — an area with limited IP saturation in this dataset and therefore higher white-space opportunity.
Atopic Dermatitis Drug Pipeline — key questions answered
IL-4Rα (Interleukin-4 Receptor Alpha) is the most heavily represented target across retrieved results. IL-4Rα is the shared chain of both type I and type II IL-4/IL-13 receptor complexes, and its blockade simultaneously interrupts IL-4 and IL-13 signaling — the dominant Th2 effector cytokines in AD. Patents spanning 2014–2026 filed by Regeneron Pharmaceuticals, Inc. and Sanofi Biotechnology across the US, EU, AU, JP, CA, IL, NZ, SG, MX, BR, PT, and HK jurisdictions collectively describe dosing regimens, biomarker-based patient selection, and pediatric extensions.
JAK inhibition broadly suppresses Th2 cytokine signaling downstream of IL-4Rα (JAK1/JAK3-STAT6 pathway), as well as JAK1/TYK2-driven itch signaling via the IL-31 axis. Pfizer Inc. discloses pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamide scaffolds as JAK inhibitors, with stated utility for JAK-mediated conditions including AD. Shenzhen Chipscreen Biosciences Co., Ltd. discloses a selective JAK3/JAK1/TBK1 inhibitor demonstrating efficacy in preclinical animal models of alopecia areata and atopic dermatitis.
IL-31, signaling through IL-31RA, is highlighted in multiple retrieved filings as a primary pruritogen directly activating itch-sensory neurons, with the DOCK8/MST1/EPAS1/SP1 transcriptional axis identified as a regulator of IL-31 expression in CD4+ T cells. Retrieved literature further notes that IL-4 promotes neural hypersensitivity to IL-31 and other pruritogens such as thymic stromal lymphopoietin (TSLP) and histamine.
Regeneron Pharmaceuticals, Inc. is the dominant assignee by volume in this dataset, with more than 20 retrieved patents across at least 12 jurisdictions (US, EP, AU, JP, CA, IL, NZ, SG, MX, BR, PT, HK). Sanofi Biotechnology appears as co-assignee on IL-4R inhibitor filings. Chugai Seiyaku Kabushiki Kaisha holds multiple anti-IL-31RA (nemolizumab) patents. Genentech, Inc./Receptos LLC and MedImmune Limited (AstraZeneca) hold IL-13 antagonist patents across multiple jurisdictions.
Retrieved results signal several combination and next-generation strategies: multispecific antibody approaches (IL-13 + IL-18, Novartis AG, 2025); anti-IL-22R antibodies (Leo Pharma A/S, 2024); anti-OX40L antibodies (Kymab Limited); anti-IL-13Rα1/eblasakimab targeting dupilumab-experienced patients (ASLAN Pharmaceuticals); IL-4/IL-13 pathway inhibitor combined with plasma cell ablation (Regeneron, 2024); and microbiome-based approaches using Akkermansia muciniphila strain EB-AMDK19 (Enterobiome Inc.).
Biomarkers identified in retrieved results for AD include CCL20, CCL22, CCL27, VEGF, IL1RA, and CCL18 — upregulated in lesional skin and modulated by anti-IL-31RA therapy (nemolizumab). These biomarkers are described as response predictors for nemolizumab treatment. Galderma Holding SA filings extend nemolizumab indication to prurigo nodularis, with responder biomarker signatures (STAT3, EGR4, KLF16, IL-6 pathway) identified as treatment effect markers.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka Your AD Pipeline QuestionsAccelerate Your Atopic Dermatitis Pipeline Research
Join 18,000+ innovators already using PatSnap Eureka to map cytokine targets, track competitor filings, and identify white-space opportunities in the AD pipeline.
References
- Methods for treating atopic dermatitis by administering an IL-4R antagonist — Regeneron Pharmaceuticals, Inc., 2014, CA [Patent]
- Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor — Regeneron Pharmaceuticals, Inc., 2018, US [Patent]
- Methods for treating atopic dermatitis by administering an IL-4R inhibitor — Regeneron Pharmaceuticals, Inc., 2026, AU [Patent]
- Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor — Regeneron Pharmaceuticals, Inc., 2024, EP [Patent]
- Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor — Regeneron Pharmaceuticals, Inc., 2019, EP [Patent]
- Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor — Sanofi Biotechnology, 2021, RU [Patent]
- Methods for treating atopic dermatitis by administering an IL-4R antagonist — Regeneron Pharmaceuticals, Inc., 2022, CA [Patent]
- Methods for treating atopic dermatitis by administering an IL-4R antagonist — Regeneron Pharmaceuticals, Inc., 2024, BR [Patent]
- Treatments for atopic dermatitis — Chugai Seiyaku Kabushiki Kaisha, 2023, US [Patent]
- Treatments for atopic dermatitis — Chugai Seiyaku Kabushiki Kaisha, 2023, WO [Patent]
- Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing IL-31 antagonist — Chugai Seiyaku Kabushiki Kaisha, 2022, AU [Patent]
- Treatments for atopic dermatitis — Chugai Seiyaku Kabushiki Kaisha, 2024, AU [Patent]
- Non-human animal model for atopic dermatitis and its use — National University Corporation Kyushu University, 2021, JP [Patent]
- Uses of IL-13 antagonists for treating atopic dermatitis — Genentech, Inc., 2024, IL [Patent]
- Uses of IL-13 antagonists for treating atopic dermatitis — Genentech, Inc., 2019, SG [Patent]
- Methods for treating atopic dermatitis and related disorders — MedImmune Limited, 2022, WO [Patent]
- Methods for treating atopic dermatitis and related disorders — MedImmune Limited, 2023, AU [Patent]
- IL-13 antibodies for the treatment of atopic dermatitis — Dermira, Inc., 2024, WO [Patent]
- IL-13 antibodies for the treatment of atopic dermatitis — Dermira, Inc., 2023, CA [Patent]
- IL-22R antibody for use in treating atopic dermatitis — Leo Pharma A/S, 2024, WO [Patent]
- Method for treatment of moderate to severe atopic dermatitis — ASLAN Pharmaceuticals Pte Ltd, 2023, WO [Patent]
- Multispecific antibodies targeting IL-13 and IL-18 — Novartis AG, 2025, ID [Patent]
- National Institutes of Health (NIH) — Atopic Dermatitis Research Resources
- World Health Organization (WHO) — Skin Disease Epidemiology
- U.S. Food and Drug Administration (FDA) — Dermatology Drug Approvals
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only — it should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.